Glaxo Proposes Biopreparedness Unit for Outbreaks Like Zika
- Drugmaker in ‘advanced discussions’ on biopreparedness unit
- Glaxo can provide facility, technology but needs commitments
This article is for subscribers only.
As the Zika virus spreads and concern grows about the world’s preparedness for outbreaks, GlaxoSmithKline Plc is proposing the creation of a unit dedicated to developing vaccines for diseases in markets offering little potential profit.
The London-based company is ready to provide a facility, staff and technology, and would welcome funding from the U.S., the U.K., the World Health Organization and other public entities, Ripley Ballou, Glaxo’s vice president of vaccines, said in a phone interview.